| Drug Type Small molecule drug | 
| Synonyms EG 017, EG017, GenSci-100 + [3] | 
| Target | 
| Action modulators | 
| Mechanism AR modulators(Androgen Receptor modulators) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization | 
| Drug Highest PhasePhase 2 | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC25H17F3N4O4 | 
| InChIKeyIZADWOHOXMTLOG-DEOSSOPVSA-N | 
| CAS Registry2442621-41-0 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Xerophthalmia | Phase 2 | China  | 20 Sep 2023 | |
| Urinary Incontinence, Stress | Phase 2 | China  | 06 Jan 2022 | |
| Urinary Incontinence, Stress | Phase 2 | China  | 06 Jan 2022 | |
| AR Positive/ER Positive/HER2 Negative Breast Cancer | Phase 1 | China  | 16 May 2023 | |
| Advanced breast cancer | Phase 1 | China  | 08 Mar 2023 | |
| Androgenetic Alopecia | Preclinical | China  | - | 





